TrialBMC medicine2025

Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis.

Xinyue Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.